Division of Neuroradiology, Joint Department of Medical Imaging, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.
Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
J Neurol Neurosurg Psychiatry. 2017 Mar;88(3):241-248. doi: 10.1136/jnnp-2016-314596. Epub 2017 Jan 18.
To systematically review and meta-analyse the data on impact of timing of endovascular treatment in aneurysmal subarachnoid haemorrhage (SAH) to determine if earlier treatment is associated with improved clinical outcomes and reduced case fatality.
We searched MEDLINE, Cochrane database, EMBASE and Web of Science to identify studies for inclusion. The measures of effect utilised were unadjusted/adjusted ORs. Effect estimates were combined using random effects models for each outcome (poor outcome, case fatality); heterogeneity was assessed using the I index. Subgroup and sensitivity analyses were performed to account for heterogeneity and risk of bias.
16 studies met the inclusion criteria. Treatment <1 day was associated with a reduced odds of poor outcome compared with treatment >1 day (OR=0.40 (95% CI 0.28 to 0.56; I=0%)) but not when compared with treatment at 1-3 days (OR=1.16 (95% CI 0.47 to 2.90; I=81%)). Treatment at <2 days and at <3 days were associated with similar odds of poor outcome compared with later treatment (OR=1.20 (95% CI 0.70 to 2.05; I=73%; OR=0.71 (95% CI 0.36 to 1.37; I=71%)). Early treatment was associated with similar odds of case fatality compared with later treatment, regardless of how early/late treatment were defined (OR=1.80 (95% CI 0.88 to 3.67; I=34%) for treatment <1 day vs days 1-3; OR=1.71 (95% CI 0.72 to 4.03; I=54%) for treatment <2 days vs later; OR=0.90 (95% CI 0.31 to 2.68; I=48%) for treatment <3 days vs later).
In only 1 of the analyses was there a statistically significant result, which favoured treatment <1 day. The inconsistent results and heterogeneity within most analyses highlight the lack of evidence for best timing of endovascular treatment in SAH patients.
系统回顾和荟萃分析血管内治疗颅内破裂动脉瘤的时间对临床结局的影响,以确定早期治疗是否与改善临床结局和降低病死率相关。
我们检索了 MEDLINE、Cochrane 数据库、EMBASE 和 Web of Science,以确定纳入的研究。使用未调整/调整后的 OR 评估效应测量。使用随机效应模型对每个结局(不良结局、病死率)进行合并效应估计;使用 I 指数评估异质性。进行亚组和敏感性分析以解释异质性和偏倚风险。
16 项研究符合纳入标准。与治疗>1 天相比,治疗<1 天与不良结局的可能性降低相关(OR=0.40(95%CI 0.28 至 0.56;I=0%)),但与治疗 1-3 天相比(OR=1.16(95%CI 0.47 至 2.90;I=81%))无显著差异。治疗<2 天和治疗<3 天与治疗较晚相比,不良结局的可能性相似(OR=1.20(95%CI 0.70 至 2.05;I=73%;OR=0.71(95%CI 0.36 至 1.37;I=71%)))。早期治疗与治疗较晚相比,病死率的可能性相似,无论如何定义早期/晚期治疗(OR=1.80(95%CI 0.88 至 3.67;I=34%)治疗<1 天与 1-3 天;OR=1.71(95%CI 0.72 至 4.03;I=54%)治疗<2 天与治疗较晚;OR=0.90(95%CI 0.31 至 2.68;I=48%)治疗<3 天与治疗较晚)。
只有 1 项分析的结果具有统计学意义,表明治疗<1 天更优。大多数分析结果不一致且存在高度异质性,突出表明缺乏关于颅内破裂动脉瘤患者最佳血管内治疗时间的证据。